Document is current
Any future updates will be listed below
-
Authors
Tokcan, Mert https://orcid.org/0009-0004-6059-1671
Wolter, Franciska Diana
Hohl, Mathias
Fries, Peter
Kessler, Thorsten
Kulenthiran, Saarraaken
Böhm, Michael
-
Funding
Funding for this research was provided by:
Hans und Ria Messer Stiftung (HMS 20243118)
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
- License Information
-
More Information
Article History
Received: 13 April 2026
Accepted: 19 May 2026
First Online: 3 June 2026
Declarations
:
: After detailed discussion of the experimental nature of the procedure and its potential risks, the patient provided written informed consent for the intervention and for publication. According to local regulations, formal ethics committee approval was not required for this compassionate-use single-case intervention. All procedures performed were in accordance with local ethical standards and with the Declaration of Helsinki and its later amendments.
: MT received personal fees from Recor Medical and is supported by the Hans und Ria Messer Stiftung (HMS 20243118). TK received personal fees from Abbott, AstraZeneca, Bristol-Myers Squibb, Recor Medical, Shockwave Medical, and Translumina. TK is named inventor on patent applications for prevention of restenosis after angioplasty and stent implantation and for the prevention and treatment of atherosclerosis using antisense oligonucleotides, all of which are unrelated to the submitted work. MB is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TTR 219, project number 322900939) and reports personal fees from Abbott, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, ReCor, Servier, and Vifor. FDW, PF, SK, and MH have nothing to disclose.
